CD40L-CD40 fuel ignites obesity

• References

• 1 Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846.
• 2 Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
• 3 Nishimura S, Manabe I, Nagasaki M. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009; 15: 914-920.
• 4 Winer S, Chan Y, Paltser G. et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009; 15: 921-929.
• 5 Feuerer M, Herrero L, Cipolletta D. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009; 15: 930-939.
• 6 Rocha VZ, Folco EJ, Sukhova G. et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res 2008; 103: 467-476.
• 7 Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-184.
• 8 Liu J, Divoux A, Sun J. et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009; 15: 940-945.
• 9 Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009; 06: 399-409.
• 10 Wu H, Ghosh S, Perrard XD. et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007; 115: 1029-1038.
• 11 Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nat Rev Immunol 2003; 03: 609-620.
• 12 Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 09: 271-285.
• 13 Poggi M, Jager J, Paulmyer-Lacroix O. et al. The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. Diabetologia 2009; 52: 1152-1163.
• 14 Engel D, Seijkens T, Poggi M. et al. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. Semin Immunol 2009; 21: 308-312.
• 15 Lievens D, Eijgelaar WJ, Biessen EA. et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206-214.
• 16 Lutgens E, Lievens D, Beckers L. et al. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 2007; 17: 118-123.
• 17 Lutgens E, Gorelik L, Daemen MJ. et al. Requirement for CD154 in the progression of atherosclerosis. NatMed 1999; 05: 1313-1316.
• 18 Lutgens E, Lievens D, Beckers L. et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207: 391-404.
• 19 Heeschen C, Dimmeler S, Hamm CW. et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111.
• 20 Desideri G, Ferri C. Effects of obesity and weight loss on soluble CD40L levels. J Am Med Assoc 2003; 289: 1781-1782.
• 21 Cipollone F, Chiarelli F, Davi G. et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005; 48: 1216-1224.
• 22 Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004; 109: 2524-2528.
• 23 Angelico F, Alessandri C, Ferro D. et al. Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. Diabetologia 2006; 49: 1169-1174.
• 24 Missiou A, Wolf D, Platzer I. et al. CD40L induces inflammation and adipogenesis in adipose cells – a potential link between metabolic and cardiovascular disease. Thromb Haemost 2010; 103: 788-796.